Name: PART 2: Dual vs Triple Anti-thrombotic Therapy for Post-PCI Patients with Atrial Fibrillation - Trials and the Differences
Uploaded: 2020-05-21T12:03:42+01:00
Duration: 25 min 57 s
Description: Prof Jan Steffel (Univerity Heart Center, Zurich, CH), Prof Jur ten Berg (St Anthonius Hospital, Nieuwegein, NL) and Prof Stefan Hohnloser (JW Goethe University, Frankfurt, DE) discuss Dual vs Triple Anti-thrombotic Therapy for Post-PCI Patients with Atrial Fibrillation - trials and the differences.

Content for healthcare professionals only

View all Platforms Cardiology

Topics Content Type Videos Articles Journals Broadcasts Education Podcasts News Journals AER CFR ECR ICR3 JAPSC USC Faculty Events Upcoming Events Radcliffe Events All Events Resource Hubs Empagliflozin in the Treatment of Chronic Heart Failure Pulmonary Embolism Pulsed Field Ablation

Radcliffe Platforms

Radcliffe Group Cardiology Vascular CVRM Medical Education

Content for healthcare professionals only

Topics

Content Type

Journals

Faculty

Events

Resource Hubs

Video

PART 2: Dual vs Triple Anti-thrombotic Therapy for Post-PCI Patients with Atrial Fibrillation - Trials and the Differences

Published: 21 May 2020

Views:
269
Likes:
0

Average (ratings)

No ratings

Your rating

Prof Jan Steffel (Univerity Heart Center, Zurich, CH), Prof Jur ten Berg (St Anthonius Hospital, Nieuwegein, NL) and Prof Stefan Hohnloser (JW Goethe University, Frankfurt, DE) discuss Dual vs Triple Anti-thrombotic Therapy for Post-PCI Patients with Atrial Fibrillation - trials and the differences.

This discussion was funded by an unrestricted educational service from Boehringer Ingelheim